Claims for Patent: 10,323,078

Summary for Patent: 10,323,078

Title:	Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases
Abstract:	A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.
Inventor(s):	Dupin; Nicolas (Colombes, FR), Grange; Philippe (Chennevieres, FR), Calvez; Vincent (Paris, FR), Raingeaud; Joel (Palaiseau, FR)
Assignee:	Universite Paris Descartes (Paris, FR) Assistance Publique--Hopitaux De Paris (Paris, FR) Universite Paris--Sud (Orsay, FR) Universite Pierre et Marie Curie (Paris 6) (Paris, FR) Institut National De La Sante et De La Recherche Medicale (INSERM) (Paris, FR) Centre National De La Recherche Scientifique (CNRS) (Paris, FR) Institut Gustave-Roussy (Villejuif, FR)
Application Number:	15/559,984
Patent Claims:	1. A method for treating and/or preventing a skin inflammatory disease comprising administering to a subject in need thereof an isolated polypeptide comprising an amino acid sequence with at least 80% identity with SEQ ID NO:1 after optimal global alignment or a fragment thereof comprising an amino acid sequence with at least 80% identity with any one of SEQ ID NOs:2, 5, 7, 8, 9, 10, 11, 12, 13, and 47 after optimal global alignment. 2. The method according to claim 1, wherein said polypeptide is selected from SEQ ID NOs:2, 5, 7, 8, 9, 10, 11, 12, 13, and 47 or a polypeptide with at least 80% identity with one of SEQ ID NOs: 2, 5, 7, 8, 9, 10, 11, 12, 13, and 47 after optimal global alignment. 3. The method according to claim 1, wherein the skin inflammatory diseases is acne. 4. The method according to claim 1, wherein said isolated polypeptide or fragment thereof inhibits the interaction with fibrinogen of at least one microbial protein involved in bacterial adhesion to a host cell. 5. The method according to claim 1, wherein the skin inflammatory disease is psoriasis. 6. The method according to claim 1, wherein said isolated polypeptide or fragment thereof inhibits the interaction with fibrinogen of at least one microbial protein involved in bacterial adhesion to a host cell, wherein the bacteria is P. acnes, and wherein the fibrinogen is human fibrinogen.

Details for Patent 10,323,078

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Gmbh	RIASTAP	fibrinogen concentrate (human)	For Injection	125317	January 16, 2009	10,323,078	2035-03-20
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA	fibrinogen (human)	For Injection	125612	June 07, 2017	10,323,078	2035-03-20